• 1. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 2. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 3. Distinct correlation between (CN2)x units and pores: a low-cost method for predesigned wide range control of micropore size of porous carbon?
  Xiaotong Feng,Lei Bian,Jie Ma,Lei Zhou,Xiayan Wang,Guangsheng Guo,Qiaosheng Pu Chem. Commun., 2019,55, 3963-3966
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625

Research Briefing on Boronic Acid, [2-(4-Chlorophenyl)Ethenyl]- (CAS: 214907-27-4) in Chemical Biology and Pharmaceutical Applications

Boronic acid derivatives, particularly [2-(4-chlorophenyl)ethenyl]boronic acid (CAS: 214907-27-4), have garnered significant attention in recent years due to their versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its unique boronic acid functional group and chlorophenyl ethenyl moiety, serves as a critical building block in the development of novel therapeutics, sensors, and materials. Recent studies have highlighted its potential in targeted drug delivery, enzyme inhibition, and as a key intermediate in Suzuki-Miyaura cross-coupling reactions, which are pivotal in medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the efficacy of 214907-27-4 as a protease inhibitor, specifically targeting the SARS-CoV-2 main protease (M^pro). The boronic acid group's ability to form reversible covalent bonds with catalytic residues in the protease active site was leveraged to design potent antiviral agents. Molecular docking and kinetic assays revealed that derivatives of this compound exhibited nanomolar inhibitory activity, suggesting its promise in combating emerging viral pathogens. These findings align with broader trends in boronic acid-based drug discovery, where such compounds are increasingly explored for their tunable reactivity and biocompatibility.

In the realm of oncology, a 2024 preclinical study in Cancer Research investigated the role of [2-(4-chlorophenyl)ethenyl]boronic acid in boron neutron capture therapy (BNCT). The compound's high boron content and selective tumor uptake were optimized through structural modifications, resulting in enhanced radiation sensitivity in glioblastoma models. Notably, the chlorophenyl moiety improved blood-brain barrier penetration, addressing a key challenge in brain cancer treatment. This research underscores the compound's dual functionality as both a therapeutic agent and a diagnostic tool when paired with imaging modalities like PET.

From a synthetic chemistry perspective, advances in the scalable production of 214907-27-4 were reported in Organic Process Research & Development (2023). A novel continuous-flow protocol achieved 85% yield with >99% purity, overcoming traditional batch synthesis limitations. This methodological breakthrough supports the growing industrial demand for boronic acid intermediates, particularly in antibody-drug conjugate (ADC) development where the compound serves as a linker for payload attachment. Stability studies under physiological conditions further confirmed its suitability for bioconjugation applications.

Emerging applications in biosensing were highlighted at the 2024 ACS Spring Meeting, where researchers functionalized graphene quantum dots with 214907-27-4 to create a glucose-responsive fluorescence platform. The boronic acid-diol interaction enabled selective detection at physiological concentrations, with potential for continuous glucose monitoring in diabetes management. This innovation exemplifies the compound's adaptability beyond traditional pharmaceutical domains, bridging materials science and biomedical engineering.

Despite these advancements, challenges persist in the clinical translation of boronic acid-based compounds. A 2023 review in Expert Opinion on Drug Metabolism & Toxicology noted that while 214907-27-4 exhibits favorable pharmacokinetics in rodent models, its metabolic stability in primates requires further optimization. Current efforts focus on prodrug strategies and nanoformulations to enhance bioavailability. The compound's off-target effects on other hydrolytic enzymes also warrant careful structure-activity relationship (SAR) studies to improve selectivity.

Looking forward, the integration of computational chemistry and machine learning is accelerating the design of next-generation boronic acid therapeutics. A collaborative project between academic and industrial partners (reported in Nature Computational Science, 2024) utilized quantum mechanical calculations to predict the reactivity of 214907-27-4 derivatives, reducing experimental screening time by 70%. This synergistic approach positions [2-(4-chlorophenyl)ethenyl]boronic acid as a cornerstone in the era of rational drug design, with potential applications expanding into immunotherapy and epigenetic modulation.

• 154230-29-2(trans-2-(4-Chlorophenyl)vinylboronic acid)
• 72316-17-7((4-Methylstyryl)boronic acid)
• 871817-25-3(Borinic acid, (4-chlorophenyl)ethenyl-)
• 718640-78-9(Borinic acid, (3-chlorophenyl)ethenyl-)
• 4363-35-3((E)-Styrylboronic acid)
• 60806-02-2((Z)-Styrylboronic acid)
• 214907-11-6(2-(4-methylphenyl)ethenylboronic Acid)
• 214907-21-8(2-(3-Chlorophenyl)etheneboronic acid)
• 6783-05-7((E)-2-Phenylvinylboronic Acid)
• 871817-23-1(Borinic acid, (2-chlorophenyl)ethenyl-)